215600.Kq

The company's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a strong equity position relative to liabilities. With a current ratio of 16.43, the company maintains a high level of liquidity, supported by cash and equivalents of 5,279,391,960 KRW. However, the company's operating cash flow is negative at -22,499,148,800 KRW, and free cash flow is also negative at -27,043,852,230 KRW, suggesting ongoing operational challenges.

Profitability metrics show a return on equity of -0.2197 and a return on assets of -0.2071, both significantly below the industry median for biotechnology firms. The company reported a net loss of -24,189,964,060 KRW, with an operating loss of -26,347,000,220 KRW, indicating a lack of profitability. These figures are not aligned with the preferred metrics for the industry, which emphasize positive returns and sustainable growth.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another. The absence of segment or geographic breakdown in the financial data further complicates the assessment of risk and growth potential.

The company's growth trajectory is constrained by its current financial performance. Revenue for the latest period was 9,225,416,500 KRW, but the company is not showing signs of growth. Analyst estimates for the next fiscal year do not indicate a significant improvement in revenue or earnings. The company's capital expenditures of -3,720,133,170 KRW suggest a focus on cost management rather than expansion.

Risk factors include the company's negative operating and free cash flows, which could impact its ability to fund operations and invest in growth. The risk assessment indicates low liquidity and dilution risk, but the absence of immediate filing-based flags does not eliminate the potential for future dilution or liquidity pressures. The company has not disclosed any dilution sources in recent filings, and no near-term dilution pressure is expected.

Recent events, including the latest financial filings and analyst estimates, show a consistent pattern of losses and negative cash flows. The company's last actual EPS was -1,481.10 KRW, and revenue was 9,068,580,000 KRW, reflecting ongoing operational challenges. No significant events or strategic initiatives have been disclosed that would suggest a turnaround in the near term.